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Wepropose that datamining and network analysis utilizing public databases can identify and quan-
tify relationships between scientific discoveries and major advances in medicine (cures). Further
development of such approaches could help to increase public understanding and governmental
support for life science research and could enhance decision making in the quest for cures.Governments and philanthropists provide
financial support for life sciences primarily
with the expectation that research will
lead to cures—defined broadly here as
measures to prevent, eradicate, or
ameliorate serious diseases. However,
public understanding of how scientific
discoveries actually result in cures is
limited, and research to elucidate princi-
ples of biological processes may appear
to non-scientists as esoteric and irrele-
vant to public expectations. Recent
examples of important cures are evident,
but public support for biomedical
research as reflected by federal funding
for the U.S. National Institutes of Health
has eroded over the past decade (FASEB
2015), indicating the absence of a strong
electoral consensus that the life science
enterprise is meeting public expectations.
Why is public support for life science
research wavering at a time when the
pace of discovery is strong and scientists
see expanding opportunity, and can ac-
tions to increase public understanding of
how new cures are developed lead to
more sustained and predictable funding
of life science?
We propose that data mining and
network analytics (Nicholson 2006; Nishi-
kawa and Motter, 2011) applied to what
we call ‘‘cure network informatics’’ could
help to increase public appreciation of
the societal value of life science discov-
eries. Thoughtful metrics emerging from
this concept perhaps can be developed
and molded into forms embraced broadly
among life scientists and by those
providing their funding and can be used
to guide decision making in ways that
would accelerate progress toward cures.Here, we describe a step in this direction
by means of an analytical model and to-
pology-based algorithms that quantify re-
lationships between scientific discoveries
and cures.
We established and automated data
collection and network analysis proto-
cols utilizing publicly accessible data-
bases, including www.fda.gov, www.
clinicaltrials.gov, www.pubmed.gov, and
www.webofknowledge.com. In a pilot
study, we considered the recently
successful applications for regulatory
approval of two new drugs: ipilimumab in
oncology and ivacaftor for cystic fibrosis.
These medical advances are sufficiently
novel and important to be reasonably
characterized as ‘‘cures’’ (vide supra). Ipi-
limumab is the first successful entry into
the new and burgeoning field of immuno-
oncology (Sharma and Allison, 2015) by
which sustained clinical remissions are
being induced in patients with previously
intractable cancers by releasing immune
effector cells from checkpoint inhibition.
Ivacaftor corrects the structure of a
specific loss-of-function mutation in the
cystic fibrosis transmembrane conduc-
tance regulator and is the first targeted
therapy of this heritable disease. Begin-
ningwith the references cited in clinical tri-
als and information provided to the U.S.
Federal Drug Administration (FDA) for reg-
ulatory approval of these drugs (FDA,
2011; FDA, 2012), we extracted two
consecutive rounds of retrospective cita-
tions and constructed network models of
articles, authors, and institutions contrib-
uting to the network. Assumptions under-
lying this approach are: (1) that the authors
of FDA applications and clinical trials willCell 163, Sappropriately cite publications reporting
new knowledge critical to the develop-
ment of a new drug candidate and (2)
that further retrospective rounds of cita-
tions will identify previous discoveries
that were most important in establishing
the base of knowledge that enabled the
successful drug development program.
We learned that the nature of a cure
discovery citation network is complex
and fundamentally collaborative with
respect to the number of different scien-
tists and institutions making contributions
to a cure. For example, the citation net-
work leading to ipilimumab includes
7,067 different scientists who listed
5,666 different institutional and depart-
mental affiliations and includes discov-
eries spanning 104 years of research
(Figure 1A). Results for ivacaftor are
similar: 2,857 different scientists from
2,516 different institutional and depart-
mental affiliations, with discoveries span-
ning 59 years of research (Figure 1B).
We next characterized individual scien-
tists within each citation network by two
metrics. Propagated in-degree rank (PIR)
is based on the number and citation count
of articles that a given author published
within the citation network and is a mea-
sure of influence within this selective set
of publications. Ratio of basic rankings
(RBR) is based on how selectively a given
author published within the cure discov-
ery citation network relative to back-
ground networks of topically related pub-
lications similar in size, scope, and
structure. This ratio helps to normalize
their overall publication output.
By applying the metrics of PIR and RBR
to the entire cure discovery citationeptember 24, 2015 ª2015 Elsevier Inc. 21
Figure 1. Cure Networks: The Constellation of Publications, Scientists, and Institutions Contributing to Drug Discovery
The red dot at the apex of the cluster is the drug ipimilumab (A) or ivacaftor (B). Relevant clinical trials and the FDA application are illustrated in brown. Publications
cited in the clinical trials and FDA applications are shown in green. Likewise, papers cited by those publications are also shown in green. Authors of the papers are
shown in purple, and institutional affiliations listed on the papers are shown in blue. The most influential contributors to the network as assessed by PIR and RBR
(see Table S1), their articles, and their institutions are highlighted in yellow with red connecting lines.network, themost influential and selective
contributors to these massive networks
emerge. Thus, in the case of ipilimumab,
15 scientists and 7 institutions associated
with 433 articles spanning 46 years
are characterized as elite performers
(Figure 1A and Table S1). Elite performers
within the ivacaftor network exhibiting
similar properties as defined by the
same metrics include 33 scientists and 7
institutions associated with 355 articles
spanning 47 years (Figure 1B and Table
S1). These elite performer subnetworks
are integral to their overall citation net-
works, serving as hubs for 31% of the
ipilimumab network and 49% of the iva-
caftor network.
These data quantify how the knowledge
base on which important advances in
medicine (‘‘cures’’) depend includes con-
tributions from a large and diverse set of
individual scientists working in many
locales. This insight should be instructive
for policymakersby suggesting that future
cureswill depend on broadly based public
support of life sciences.Narrowly targeted
funding initiatives may well have value but
are unlikely in isolation to generate the
breadth of new knowledge required to
lay the foundation for future cures.
We call on the scientific community to
embrace and advance the concept of22 Cell 163, September 24, 2015 ª2015 Elsecure network informatics so as to develop
advanced and sophisticated analytical
tools to increase understanding of how
scientific discoveries lead to cures,
including predictive metrics that may
guide decision making with respect to
work in progress. All of the code neces-
sary to reproduce and extend this initial
effort is freely available and open source
(Lotia and Pico, 2015). This network infor-
matics approach can be applied to any
‘‘cure’’ with a cited publication trail. Cura-
tors of publically available databases
could play important roles in these efforts
by considering cure network informatics
in the design of database architecture
and embedded tools. It will be important
to identify trends that hold across all cures
and ones that are specific to certain types
of cures. It will also be useful to identify
features of hubs within cure networks
that are essential to the flow of knowledge
required to create a cure.
A need for better metrics for assessing
performance and for decision support
within the life sciences is widely acknowl-
edged by leaders and commentators in
biomedicine (Sarli and Carpenter, 2014;
University of Gothenburg, 2013). Metrics
that are readily understandable by non-
scientists, grounded in outcomes that
the general public values highly (cures),vier Inc.and faithful to what scientists know to be
the richly intersecting and often unpre-
dictable nature of scientific discovery
should be more useful for influencing pol-
icy makers than currently available alter-
natives. Further development of new and
useful tools for cure network informatics
should contribute to increased public
trust in, and support for, the life science
enterprise.SUPPLEMENTAL INFORMATION
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